Management of symptomatic uterine fibroids with ulipristal acetate: A retrospective, multicentric and nationwide study

Bulun, 2013, Mechanisms of disease: uterine fibroids, N Engl J Med, 369, 1344, 10.1056/NEJMra1209993 Donnez, 2012, Ulipristal acetate versus placebo for fibroid treatment before surgery, N Engl J Med, 366, 409, 10.1056/NEJMoa1103182 Lukes, 2019, Health-related quality of life with ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial, Obstet Gynecol, 133, 869, 10.1097/AOG.0000000000003211 Stewart, 2018 Wechter, 2011, Leiomyoma-related hospitalization and surgery: prevalence and predicted growth based on population trends, Am J Obstet Gynecol, 205, 492.e1, 10.1016/j.ajog.2011.07.008 Donnez, 2015, Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids, Fertil Steril, 103, 519, 10.1016/j.fertnstert.2014.10.038 Donnez, 2016, Long-term medical management of uterine fibroids with ulipristal acetate, Fertil Steril, 10.1016/j.fertnstert.2015.09.032 Garnock-Jones, 2017, Ulipristal acetate: a review in symptomatic uterine fibroids, Drugs, 77, 1665, 10.1007/s40265-017-0812-3 Donnez, 2019, Fibroid management in premenopausal women, Climacteric, 22, 27, 10.1080/13697137.2018.1549216 Singh, 2015, Contemporary management of uterine fibroids: focus on emerging medical treatments, Curr Med Res Opin, 31, 1, 10.1185/03007995.2014.982246 Jacobson, 2007, Changes in rates of hysterectomy and uterine conserving procedures for treatment of uterine leiomyoma, Am J Obstet Gynecol, 196, 10.1016/j.ajog.2007.03.009 Borah, 2016, Association between patient characteristics and treatment procedure among patients with uterine leiomyomas, Obstet Gynecol, 127, 67, 10.1097/AOG.0000000000001160 Verguts, 2019, Effect on surgical decisions: ulipristal acetate as key player in Belgian phase IV registration trial, Int J Gynecol Obstet, 147, 339, 10.1002/ijgo.12968